(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Bipolar II Disorder
Joshua RosenblatSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Bipolar II Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Massachusetts General Hospital | Phase 4 | BBB |
Valproic Acid National Cheng-Kung University Hospital | Phase 4 | BB |
Seroquel® First Affiliated Hospital of Zhejiang University | Phase 4 | BB |
VENLOR Stanley Medical Research Institute | Phase 4 | BB |
Bxcl501 BioXcel Therapeutics Inc | Phase 3 | BB |
View all 27 →
Same molecule, other indications
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →